drugset / Trial / NCT02117752

Dermal Tolerability of Dapsone Gel in Healthy Volunteers

NCT02117752

Phase 1 Completed 237 enrolled Almirall, S.A. Allergan · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will determine the cumulative irritation potential and sensitization potential of dapsone gel and vehicle after repeat applications on the skin of healthy volunteers.

Timeline

Start
2014-04
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapsone Small molecule Topical

Indications

No indication recorded.